Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06923631

Unravelling the Measles Paradox in Children

Measles is caused by measles virus (MeV). The disease is associated with lymphopenia and immune suppression, which is an important cause of measles-associated morbidity and mortality. Measles-induced immune suppression can last several years, whereas measles lymphopenia is usually resolved within two weeks. At the same time, measles induces lifelong immunity. This apparent contradiction, known as the 'measles paradox', was partially solved when investigators demonstrated that MeV infects and depletes pre-existing memory cells, thereby causing 'immune amnesia'. This model is supported by observations in animal models and clinical studies, but several questions remain to be addressed, like the duration of measles-induced amnesia and changes in the immune repertoire after measles. to address the immunological questions regarding MeV infection.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

4 year–17 year

Sex eligibility

All sexes

Study type

Observational

Primary location

ErasmusMC

Rotterdam, South Holland, 3015GD, Netherlands

About this study

Measles is caused by measles virus (MeV). The disease is associated with lymphopenia and immune suppression, which is an important cause of measles-associated morbidity and mortality. Measles-induced immune suppression can last several years, whereas measles lymphopenia is usually resolved within two weeks. At the same time, measles induces lifelong immunity. This apparent contradiction, known as the 'measles paradox', was partially solved when investigators demonstrated that MeV infects and depletes pre-existing memory cells, thereby causing 'immune amnesia'. This model is supported by observations in animal models and clinical studies, but several questions remain to be addressed, like the duration of measles-induced amnesia and changes in the immune repertoire after measles. Recently, investigators have acquired permission to address these remaining questions in 18-25 years old adults (MEC-2024-0230). However, investigators have reservations about the feasibility of including enough participants between 18 and 25 years old that have not been vaccinated against or infected with MeV; it is possible that investigators will not reach sufficient inclusions to address the immunological questions regarding MeV infection in that protocol. Therefore, investigators propose to additionally study these questions in children in the age of 4 up to and including 17.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Group A

  • Aged 4 - 17 years old
  • Susceptible to measles
  • No pre-existing immunity against measles (vaccination or earlier infection)

Group B

  • Aged 4 - 17 years old
  • Protected against measles due to vaccination or earlier infection

Exclusion criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study:

  • Diagnosed chronic disease that lasted over 3 months
  • Immune suppression (due to medication or underlying disease)
  • Group A; Detectable MeV-antibodies in the T1 blood sample

Treatment and study plan

Primary outcomes

  1. Compare measles-induced loss of pathogen-specific antibodies

    Time frame: 36 months

    The investigators will measure changes in the immune repertoire using longitudinal samples obtained from children who are infected with MeV. To this end, they will measure pathogen-specific antibody responses (titers) pre- and post-measles and compare these to determine whether measles led to a loss of pathogen-specific antibodies.

  2. Compare measles-induced loss of pathogen-specific T-cells

    Time frame: 36 months

    The investigators will measure changes in the immune repertoire using longitudinal samples obtained from children who are infected with MeV. To this end, they will measure pathogen-specific T-cell responses (frequencies) pre- and post-measles and compare these to determine whether measles led to a loss of pathogen-specific T-cells.

Study contacts

Contact information is provided by the study sponsor or research team.

Dr C.H. Geurts van Kessel

CONTACT

[email protected]

+31643271384

Sponsors and collaborators

Lead sponsor

Erasmus Medical Center

Other

Registry information

Official study title

Unravelling the Measles Paradox in Children: a Disease Associated With Both Immune Suppression and Immune Activation

Acronym: MISIA-k

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Apr 11, 2025
Registry last updated
Nov 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.